Screener
Supernus Pharmaceuticals SUPN Invested capital
Discontinued — last reported Q1 '26
Invested capital at other companies
Other financials
Where this comes from
Calculated from Supernus Pharmaceuticals’s reported figures.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
FAQ
- What is Supernus Pharmaceuticals's invested capital?
- Supernus Pharmaceuticals (SUPN) reported invested capital of $931.39M in Q1 2026.
- How has Supernus Pharmaceuticals's invested capital changed year-over-year?
- Supernus Pharmaceuticals's invested capital decreased by 1.7% year-over-year, from $947.16M to $931.39M.
- What is the long-term trend for Supernus Pharmaceuticals's invested capital?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's invested capital has grown at a 13.5% compound annual growth rate (CAGR), from $516.31M to $972.79M.
- What does invested capital mean?
- Total debt plus shareholders' equity minus cash, at the quarter end. The capital actually put to work in the operating business — the denominator of return on invested capital (ROIC).
Ask your AI about Supernus Pharmaceuticals's invested capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude